Global Erythropoietin Drugs Market Expected to Be Worth US $19,379.2 Mn by 2025

The global erythropoietin drugs market is expected to be worth US$19,379.2 mn by the end of 2025, as the market rises at a steady CAGR of 7.5% between 2017 and 2025.


Albany, NY -- (SBWIRE) -- 01/02/2018 -- This research report offers a comprehensive analysis of the "Glycated Hemoglobin Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017 - 2026"The main objective of this report is to deliver insightful information and clear-cut facts pertaining to the growth trajectories of the market.

Request to view Sample Report @

Advancements in the field of diagnostics have come a long way in enabling medical professionals to enhance the lives of chronically-ill patients. Increasing incidence of diabetes around the world has spiked the use of diagnostic methods such as glycated hemoglobin tests. Manufacturers of medical devices are actively focusing on creating new products that serve the critical purpose of glycated hemoglobin testing in the diagnosis of diabetes. An exclusive research report by Transparency Market Research reveals that the growing incidence of diabetes will continue to drive the growth of the global glycated hemoglobin testing market in the foreseeable future.

According to the study, the global market for glycated hemoglobin testing will be worth US$ 705 million by the end of 2026. The report projects that improvements in the techniques and increasing preference of diabetics towards early diagnosis will drive the adoption of glycated hemoglobin testing in the near future. During the forecast period, 2017-2026, the global glycated hemoglobin testing market is anticipated to expand robustly at a CAGR of 8.8%.

North America to Register Highest Adoption of Glycated Hemoglobin Tests

Key findings from the research study reveal that the demand for glycated hemoglobin testing services is the highest in the US and Canada. Consumers in North America are highly prone to diabetes as their proactive lifestyles and hectic professions lead them towards unhealthy diets. In 2017, North America glycated hemoglobin testing market is anticipated to be worth US$ 113 million. During the forecast period, the demand for glycated hemoglobin testing in Europe and the Asia-Pacific excluding Japan region is also expected to gain considerable traction.

Increasing Uptake for Laboratory Based Tests

Patients seeking glycated hemoglobin testing are growing more inclined towards laboratory based tests. While point-of-care glycated hemoglobin testing is more convenient option, the results and diagnostic outcomes of laboratories continue to spearhead their dominance in the global market. By the end of 2026, nearly US$ 500 million worth of glycated hemoglobin tests will be performed in laboratories. However, during the forecast period, point-of-care tests are anticipated to record fastest revenue growth at a CAGR of 10.6%.

Browse Full Report with TOC @

Higher End-use in Hospitals; Equal Preference to Immunoassay and Chromatography Techniques

The report further reveals that hospitals will be the largest end-users of glycated hemoglobin testing in the global market. Through 2026, over one-third share of revenues procured in the global glycated hemoglobin testing market will be accounted by their end-use in hospitals. Diagnostic centers will also be leading end-users of glycated hemoglobin testing, while academic institutes will exhibit moderate traction in terms of adoption. On the basis of techniques, the global market for glycated hemoglobin testing will witness near-equal revenue share from chromatography and immunoassay techniques. With respect to identifying the average concentration of plasma glucose in blood, these techniques are equally effective and affordable. By 2026, revenues accounted by chromatography and immunoassays will individually bring in more than US$ 315 million to the global market value.

Competition Tracking

Several manufacturers of medical devices across the globe have deeply invested in the expansion of the global glycated hemoglobin testing market. In the view of growing contribution of diabetes to revenues of pharmaceutical companies and medical device manufacturers, the overall glycated hemoglobin testing market is likely to remain lucrative in the healthcare sector. Companies namely, Arkray, Bayer, Bio-Rad Laboratories, Ceragem Medisys, Chek Diagnostics, Daiichi Biotech, DiaSys Diagnostic Systems, Diazyme Laboratories, EKF Diagnostics, Erba Mannheim, Human Diagnostics, Lite-On Technology, Menarini, Mindray Medical, Randox Laboratories, Sebia, Siemens Healthcare, TaiDoc Technology, Tosoh Bioscience, and Trinity Biotech are observed as key market participants in the global glycated hemoglobin testing market. Their presence in the expansion of the global market for glycated hemoglobin testing during the forecast period is expected to be active and aggressive.

Enquire about this Report @

About (MRRSE)
Market Research Reports Search Engine (MRRSE) is an industry-leading database of Market Research Reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE's repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

Contact Us                                                                         
State Tower
90, State Street
Suite 700
Albany, NY - 12207
United States Telephone: +1-518-730-0559
Read More Industry News At: